The licensed small molecule program aims to address significant unmet needs for autoimmune diseases.
Program adds to Boehringer's pipeline and its commitment to deliver breakthrough t...
The Group moves into Fiscal 2026 on strengthened foundations
Fiscal 2025 Results
Issy-les-Moulineaux, France – 30 October 2025
Pluxee outperforms in Fiscal 2025, combining sustained growth, strong ...
